NEW YORK, Feb. 22 (GenomeWeb News) - Illumina has signed a definitive agreement to acquire CyVera, a developer of a microbead-based biological assay platform, for $17.5 million in cash and stock, Illumina said today.
Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.
In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.
